Therapeutic Potential of Amniotic Fluid-Derived Stem Cells into Pancreatic Lineage in an Animal Model of Diabetes

L. Rastogi, S. Nityanand
{"title":"Therapeutic Potential of Amniotic Fluid-Derived Stem Cells into Pancreatic Lineage in an Animal Model of Diabetes","authors":"L. Rastogi, S. Nityanand","doi":"10.36647/tbeah/04.01.a002","DOIUrl":null,"url":null,"abstract":"Diabetes is a major health concern and it is estimated that India became diabetic capital in the future. The therapeutic potential of various medications, cell therapy, and islet transplantation is explored in recent years. The therapeutic potential of Mesenchymal Stem cells (MSCs) from bone marrow and from other sources has been studied forthe treatment of diabetes. MSCsfrom bone marrow ameliorate hyperglycemia but are unable to restore normoglycaemia in diabetic animals when injected with a single dose. The therapeutic potential of another more primitive source of MSCs from human amniotic fluid-derived stem cells (hAFSCs) has not been explored in diabetes. In the present study, we have assessed the effect of hAFSCs in a rat model of diabetes. hAFSCs transplantation has been seen to control blood glucose levels, and promote weight gain and other physiological parameters. Immuno-histochemical results suggested an increase in islet mass and number after hAFSCs transplantation. Q-RTPCR results showed transcription factors Ins-1, Oct-4, MAF-A, and PDX-1 were markedly upregulated in the hAFSCs transplanted group in comparison with diabetes and control groups. These data suggest that hAFSCs possess considerable therapeutic potential for diabetes through the restoration of insulin mass and up regulations of transcription factors of pancreatic lineage. Keyword : Amniotic fluid stem cells, diabetic mellitus, rat","PeriodicalId":145122,"journal":{"name":"Transaction on Biomedical Engineering Applications and Healthcare","volume":"3 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transaction on Biomedical Engineering Applications and Healthcare","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36647/tbeah/04.01.a002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetes is a major health concern and it is estimated that India became diabetic capital in the future. The therapeutic potential of various medications, cell therapy, and islet transplantation is explored in recent years. The therapeutic potential of Mesenchymal Stem cells (MSCs) from bone marrow and from other sources has been studied forthe treatment of diabetes. MSCsfrom bone marrow ameliorate hyperglycemia but are unable to restore normoglycaemia in diabetic animals when injected with a single dose. The therapeutic potential of another more primitive source of MSCs from human amniotic fluid-derived stem cells (hAFSCs) has not been explored in diabetes. In the present study, we have assessed the effect of hAFSCs in a rat model of diabetes. hAFSCs transplantation has been seen to control blood glucose levels, and promote weight gain and other physiological parameters. Immuno-histochemical results suggested an increase in islet mass and number after hAFSCs transplantation. Q-RTPCR results showed transcription factors Ins-1, Oct-4, MAF-A, and PDX-1 were markedly upregulated in the hAFSCs transplanted group in comparison with diabetes and control groups. These data suggest that hAFSCs possess considerable therapeutic potential for diabetes through the restoration of insulin mass and up regulations of transcription factors of pancreatic lineage. Keyword : Amniotic fluid stem cells, diabetic mellitus, rat
羊水衍生干细胞在糖尿病动物模型中的胰腺系治疗潜力
糖尿病是一个主要的健康问题,据估计,印度未来将成为糖尿病之都。近年来,人们探索了各种药物、细胞疗法和胰岛移植的治疗潜力。骨髓间充质干细胞和其他来源的间充质干细胞在治疗糖尿病方面的潜力已得到研究。骨髓间充质干细胞可改善糖尿病动物的高血糖症状,但单次注射无法恢复正常血糖。另一种更原始的间充质干细胞来源--人羊水干细胞(hAFSCs)--在糖尿病中的治疗潜力尚未得到探索。在本研究中,我们评估了hAFSCs对糖尿病大鼠模型的影响。移植hAFSCs可控制血糖水平,促进体重增加和其他生理指标。免疫组化结果表明,hAFSCs 移植后胰岛质量和数量增加。Q-RTPCR结果显示,与糖尿病组和对照组相比,hAFSCs移植组转录因子Ins-1、Oct-4、MAF-A和PDX-1明显上调。这些数据表明,通过恢复胰岛素质量和上调胰腺转录因子,hAFSCs对糖尿病具有相当大的治疗潜力。关键词 :羊水干细胞 糖尿病 大鼠
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信